An India Today investigation into lax enforcement of drug norms that make accessing prescription-only medicines easy, and rising misuse of weight-loss drugs in the country.

Novo Nordisk NVO shares have plunged 20.5% in the past month. The massive sell-off of the stock was primarily driven by a weaker-than-expected 2026 financial outlook issued by the company, despite its ...

By Hugo Francisco de Souza New clinical trial evidence suggests targeting both obesity and sleep-disordered breathing ...

Add Yahoo as a preferred source to see more of our stories on Google. -Credit:Reach Publishing Services Limited (Reach Publishing Services Limited) Health experts have warned of the dangers of a new ...

Postmenopausal women taking tirzepatide and hormone therapy lost more body weight than those on tirzepatide alone. Hormone therapy users also had additional improvements in diastolic blood pressure, ...

Health experts have warned of the dangers of a new weight-loss trend dubbed the "golden dose" rapidly gaining traction on social media, with users sharing videos and tips on how to extract what they ...

Postmenopausal women who used hormone therapy lost significantly more weight while taking tirzepatide than women only taking tirzepatide.

Once-weekly subcutaneous tirzepatide administered for 72 weeks was not associated with an increased risk for depression compared with placebo in adults with overweight or obesity, with or without type ...

The company is banking on its Wegovy pill and next-generation weight loss injectable CagriSema to recapture share of the key U.S. market.

MEDVi has a physician-monitored telehealth platform that enables patients to receive GLP-1 weight loss therapy through linking with licensed clinicians, compounded drugs via licensed pharmacies and ...